Subscribe
wavebreakmedia-shutterstock-com-4
wavebreakmedia / Shutterstock.com
21 June 2016Americas

NIH chooses not to use ‘march-in rights’ in prostate drug row

The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.
article
NIH COVID-19 deal broadens access for poorer nations
19 May 2022   The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.
article
NIH COVID-19 deal broadens access for poorer nations
19 May 2022   The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.

More on this story

Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.
article
NIH COVID-19 deal broadens access for poorer nations
19 May 2022   The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims